retatrutide

News

Eli Lilly has revealed more data with its triple G agonist retatrutide, boosting its credentials as the next big thing in cardiometabolic diseases.

News

Eli Lilly has sued six US-based companies it accuses of participating in an illegal black market for experimental weight-loss drug retatrutide.

News

Armed with new pivotal trial results, Eli Lilly is preparing to file for approval of its triple-acting weight-loss therapy, retatrutide, next year.

News

Lilly reveals more details of its retatrutide obesity and diabetes studies, plus trial updates from Zealand/Roche, Pfizer, Novo Nordisk, and Sciwind.

News

Lilly's retatrutide achieved weight loss of more than 30% at two years in a new trial, firming up its credentials as a next-generation obesity drug.

News

Novo Nordisk has reported the first clinical data with its triple G agonist for diabetes, in China, as it starts an international trials programme.